Embora seja uma das áreas mais ameaçadas na Terra, há poucos estudos sobre o potencial farmacológico da Caatinga. Este bioma é exclusivamente brasileiro e as plantas encontradas na região apresentam características únicas que as tornam fontes imensuráveis de compostos ativos. O parasito Trichomonas vaginalis é o agente etiológico da tricomoníase, a doença sexualmente transmissível não viral mais comum no mundo. A infecção está associada a sérias consequências em saúde e casos de resistência ao fármaco de escolha, metronidazol, estão em constante crescimento. Desta forma, a necessidade por alternativas para o tratamento da tricomoníase é evidente. O objetivo desta tese foi avaliar o potencial anti-T. vaginalis de plantas oriundas da Caatinga. A planta Manilkara rufula apresentou a mais potente atividade frente ao parasito e um fracionamento bioguiado foi realizado. Triterpenos pentacíclicos (caproato de α- e β-amirina, acetato de β-amirina e lupeol) foram identificados nas frações apolares de M. rufula, porém com baixa atividade antiparasitária. Derivados triterpênicos semissintéticos, frações contendo flavonoides, taninos e saponinas também foram testados. Nossos resultados demonstraram que o ácido ursólico e a fração H100 apresentaram potente atividade anti-T. vaginalis e ambos afetaram o crescimento e viabilidade dos trofozoítos. Além disso, o ácido ursólico e a fração H100 induziram importantes alterações na ultraestrutura dos organismos, indicando que o mecanismo de morte do parasito ocorreu por danos na membrana. A fração H100 induziu a lise total de eritrócitos e reduziu a adesão dos parasitos às células epiteliais, sugerindo, novamente, a ação sobre membrana. A fração H100 não apresentou citotoxicidade às células epiteliais. Os resultados apresentados demonstraram o potencial da planta M. rufula contra T. vaginalis e contribuem para o entendimento das propriedades farmacológicas das plantas da Caatinga, bem como para o desenvolvimento racional de alternativas para o tratamento da tricomoníase. / Although it is one of the most endangered areas on Earth, there are few studies on the pharmacological potential of the Caatinga. This is an exclusively Brazilian biome and its plants present unique characteristic that make them an immeasurable source of active compounds. The parasite Trichomonas vaginalis is the etiologic agent of trichomoniasis, the most common non-viral sexually transmitted disease worldwide. The infection has been associated with serious consequences in health and cases of resistance to metronidazole are constantly increasing. Then, the necessity of new alternatives to the treatment of trichomoniasis is evident. The aim of this thesis was to evaluate the anti-T. vaginalis potential of plants from Caatinga. The Manilkara rufula plant showed the most potent activity against the parasite and bioguided fractionation was performed. Pentacyclic triterpenes (α- and β-amyrin caproate and β-amyrin and lupeol acetate) were identified in the nonpolar fractions of M. rufula, however, low antiparasitic activity was observed. Triterpenic semisynthetic derivatives, fractions containing flavonoids, tannins and saponins were also tested. Our results showed that ursolic acid and H100 fraction exhibited potent anti-T. vaginalis activity and both affect growth and viability of trophozoites. In addition, ursolic acid and H100 fraction induced significant alterations in the ultrastructure of the parasite, indicating that the mechanism of death is by membrane damage. The H100 fraction induced complete lysis of erythrocytes and reduced the parasites adhesion to epithelial cells, once again, suggesting that the H100 action was on parasite membrane. The fraction H100 showed no cytotoxicity to epithelial cells. The results demonstrated the potential of the plant M. rufula against T. vaginalis and contributed to the understanding of the pharmacological properties of the Caatinga plants, as well as for the rational development of alternatives for trichomoniasis treatment.

Tricomoníase é a doença sexualmente transmissível não-viral mais comum no mundo e pode gerar sérias consequências na saúde reprodutiva, câncer e transmissão e aquisição do HIV. Por esta razão, esta infecção resulta em um pesado fardo para os sistemas de saúde pública. O único tratamento aprovado para esta infecção, que consiste nos 5-nitromidazois metronidazol e tinidazol, apresenta efeitos adversos e há uma subestimada taxa de resistência da infecção, atualmente considerada uma doença negligenciada, a estes fármacos. Portanto, há uma necessidade urgente de novas alternativas terapêuticas para a tricomoníase. Chalconas são uma família de moléculas que apresenta várias aplicações biológicas, como atividade contra diversos patógenos, incluindo protozoários patogênicos. Este trabalho apresenta o potencial anti-Trichomonas vaginalis de derivados de chalcona sintetizados e seus efeitos sobre os trofozoítos. Os valores de IC50 dos compostos mais ativos variaram de 27,5 a 76,4 μM, e as moléculas 4’-hidroxichalcona e 3’-aminochalcona apresentaram os valores mais baixos (27,5 e 28,9 μM). Estes dois compostos foram citotóxicos contra a linhagem de células epiteliais vaginais HMVII, consequentemente apresentaram baixos Índices de Seletividade; contudo, ao se utilizar larvas de Galleria mellonella, como modelo de toxicidade in vivo, não foi observada diminuição da viabilidade após o tratamento. As moléculas também não provocaram hemólise em eritrócitos humanos em 1 e 24 horas. Os compostos não induziram significativa produção de espécies reativas de oxigênio (EROs) nos trofozoítos. Neutrófilos humanos apresentaram aumento na produção de EROs quando coincubados com trofozoítos tratados com os compostos. Os resultados indicam que as chalconas são uma família de moléculas com potencial atividade contra T. vaginalis. / Trichomoniasis is the most common non-viral sexually transmitted disease worldwide and can lead to serious consequences in reproductive health, cancer and HIV acquisition. For this reason, this infection results in a heavy burden for public health systems. Current approved treatment, which consists in 5-nitromidazole drugs, metronidazole and tinidazole, present adverse effects and there is underestimate drug resistance data on this parasitic infection, currently considered a neglected disease. Therefore, there is an urgent need for new alternatives for trichomoniasis treatment. Chalcones are a family of molecules that present various biological applications, such as activity against many pathogenic organisms including protozoan pathogens. This study presents the anti-Trichomonas vaginalis potential of synthetized chalcone derivatives and their effects on the trophozoites. IC50 values of the most active compounds ranged from 27.5 to 76.4 μM, and 4’-hydroxychalcone and 3’- aminochalcone presented the lowest values of IC50 (27.5 and 28.9 μM). These two compounds showed cytotoxicity against HMVII vaginal epithelial cells, thus presenting a low Selectivyty Index; however, when Galleria mellonella larvae were used as model for in vivo toxicity no significant decrease in viability after treatment was observed. The chalcones also did not induce hemolysis in human erythrocytes The compounds did not induce significant reactive oxygen species (ROS) production in the trophozoites. Human neutrophils have increased ROS production when exposed to treated trophozoites. Results indicate that chalcones are a family of molecules with potential activity against T. vaginalis.

Embora seja uma das áreas mais ameaçadas na Terra, há poucos estudos sobre o potencial farmacológico da Caatinga. Este bioma é exclusivamente brasileiro e as plantas encontradas na região apresentam características únicas que as tornam fontes imensuráveis de compostos ativos. O parasito Trichomonas vaginalis é o agente etiológico da tricomoníase, a doença sexualmente transmissível não viral mais comum no mundo. A infecção está associada a sérias consequências em saúde e casos de resistência ao fármaco de escolha, metronidazol, estão em constante crescimento. Desta forma, a necessidade por alternativas para o tratamento da tricomoníase é evidente. O objetivo desta tese foi avaliar o potencial anti-T. vaginalis de plantas oriundas da Caatinga. A planta Manilkara rufula apresentou a mais potente atividade frente ao parasito e um fracionamento bioguiado foi realizado. Triterpenos pentacíclicos (caproato de α- e β-amirina, acetato de β-amirina e lupeol) foram identificados nas frações apolares de M. rufula, porém com baixa atividade antiparasitária. Derivados triterpênicos semissintéticos, frações contendo flavonoides, taninos e saponinas também foram testados. Nossos resultados demonstraram que o ácido ursólico e a fração H100 apresentaram potente atividade anti-T. vaginalis e ambos afetaram o crescimento e viabilidade dos trofozoítos. Além disso, o ácido ursólico e a fração H100 induziram importantes alterações na ultraestrutura dos organismos, indicando que o mecanismo de morte do parasito ocorreu por danos na membrana. A fração H100 induziu a lise total de eritrócitos e reduziu a adesão dos parasitos às células epiteliais, sugerindo, novamente, a ação sobre membrana. A fração H100 não apresentou citotoxicidade às células epiteliais. Os resultados apresentados demonstraram o potencial da planta M. rufula contra T. vaginalis e contribuem para o entendimento das propriedades farmacológicas das plantas da Caatinga, bem como para o desenvolvimento racional de alternativas para o tratamento da tricomoníase. / Although it is one of the most endangered areas on Earth, there are few studies on the pharmacological potential of the Caatinga. This is an exclusively Brazilian biome and its plants present unique characteristic that make them an immeasurable source of active compounds. The parasite Trichomonas vaginalis is the etiologic agent of trichomoniasis, the most common non-viral sexually transmitted disease worldwide. The infection has been associated with serious consequences in health and cases of resistance to metronidazole are constantly increasing. Then, the necessity of new alternatives to the treatment of trichomoniasis is evident. The aim of this thesis was to evaluate the anti-T. vaginalis potential of plants from Caatinga. The Manilkara rufula plant showed the most potent activity against the parasite and bioguided fractionation was performed. Pentacyclic triterpenes (α- and β-amyrin caproate and β-amyrin and lupeol acetate) were identified in the nonpolar fractions of M. rufula, however, low antiparasitic activity was observed. Triterpenic semisynthetic derivatives, fractions containing flavonoids, tannins and saponins were also tested. Our results showed that ursolic acid and H100 fraction exhibited potent anti-T. vaginalis activity and both affect growth and viability of trophozoites. In addition, ursolic acid and H100 fraction induced significant alterations in the ultrastructure of the parasite, indicating that the mechanism of death is by membrane damage. The H100 fraction induced complete lysis of erythrocytes and reduced the parasites adhesion to epithelial cells, once again, suggesting that the H100 action was on parasite membrane. The fraction H100 showed no cytotoxicity to epithelial cells. The results demonstrated the potential of the plant M. rufula against T. vaginalis and contributed to the understanding of the pharmacological properties of the Caatinga plants, as well as for the rational development of alternatives for trichomoniasis treatment.

Tricomoníase é a doença sexualmente transmissível não-viral mais comum no mundo e pode gerar sérias consequências na saúde reprodutiva, câncer e transmissão e aquisição do HIV. Por esta razão, esta infecção resulta em um pesado fardo para os sistemas de saúde pública. O único tratamento aprovado para esta infecção, que consiste nos 5-nitromidazois metronidazol e tinidazol, apresenta efeitos adversos e há uma subestimada taxa de resistência da infecção, atualmente considerada uma doença negligenciada, a estes fármacos. Portanto, há uma necessidade urgente de novas alternativas terapêuticas para a tricomoníase. Chalconas são uma família de moléculas que apresenta várias aplicações biológicas, como atividade contra diversos patógenos, incluindo protozoários patogênicos. Este trabalho apresenta o potencial anti-Trichomonas vaginalis de derivados de chalcona sintetizados e seus efeitos sobre os trofozoítos. Os valores de IC50 dos compostos mais ativos variaram de 27,5 a 76,4 μM, e as moléculas 4’-hidroxichalcona e 3’-aminochalcona apresentaram os valores mais baixos (27,5 e 28,9 μM). Estes dois compostos foram citotóxicos contra a linhagem de células epiteliais vaginais HMVII, consequentemente apresentaram baixos Índices de Seletividade; contudo, ao se utilizar larvas de Galleria mellonella, como modelo de toxicidade in vivo, não foi observada diminuição da viabilidade após o tratamento. As moléculas também não provocaram hemólise em eritrócitos humanos em 1 e 24 horas. Os compostos não induziram significativa produção de espécies reativas de oxigênio (EROs) nos trofozoítos. Neutrófilos humanos apresentaram aumento na produção de EROs quando coincubados com trofozoítos tratados com os compostos. Os resultados indicam que as chalconas são uma família de moléculas com potencial atividade contra T. vaginalis. / Trichomoniasis is the most common non-viral sexually transmitted disease worldwide and can lead to serious consequences in reproductive health, cancer and HIV acquisition. For this reason, this infection results in a heavy burden for public health systems. Current approved treatment, which consists in 5-nitromidazole drugs, metronidazole and tinidazole, present adverse effects and there is underestimate drug resistance data on this parasitic infection, currently considered a neglected disease. Therefore, there is an urgent need for new alternatives for trichomoniasis treatment. Chalcones are a family of molecules that present various biological applications, such as activity against many pathogenic organisms including protozoan pathogens. This study presents the anti-Trichomonas vaginalis potential of synthetized chalcone derivatives and their effects on the trophozoites. IC50 values of the most active compounds ranged from 27.5 to 76.4 μM, and 4’-hydroxychalcone and 3’- aminochalcone presented the lowest values of IC50 (27.5 and 28.9 μM). These two compounds showed cytotoxicity against HMVII vaginal epithelial cells, thus presenting a low Selectivyty Index; however, when Galleria mellonella larvae were used as model for in vivo toxicity no significant decrease in viability after treatment was observed. The chalcones also did not induce hemolysis in human erythrocytes The compounds did not induce significant reactive oxygen species (ROS) production in the trophozoites. Human neutrophils have increased ROS production when exposed to treated trophozoites. Results indicate that chalcones are a family of molecules with potential activity against T. vaginalis.

Advances in DNA sequencing led to a technological breakthrough, that allowed analyzis of complete genomes including those of parasitic protists Trichomonas vaginalis and Giardia intestinalis . These organisms are studied not only for their clinical importance, but also from the evolutionary point of view for their adaptation to anaerobic environment. Genome sequencing and annotations of predicted proteins alone did not bring detail view into functioning of their mitochondrion related organelles ­ in G. intestinalis mitosomes, not­participating in energetic metabolism, in T. vaginalis hydrogenosomes, producing molecular hydrogen and ATP by means of substrate phosphorylation. Traditional methods based on a fractionation by ultracentrifuging in density gradient and subsequent biochemical and enzymological analyzes were extended by one­ and two­dimensional electrophoresis with subsequent identification of proteins by mass spectrometry. Methods of multidimensional separation of peptides produced by specific proteolysis of a complex mixture...

Trichomonas vaginalis and Tritrichomonas foetus are the etiologic agents of human and bovine trichomoniasis, respectively. As microaerophilic protozoans; both share a wide array of clinical manifestations ranging from vaginitis to abnormal pregnancies. Human trichomoniasis receives minimal public health attention despite of its worldwide high prevalence rate. Emerging evidence of metronidazole-resistant T vaginalis strains facilitates a concern to understand this protozoan. Cysteine proteases have been implicated as important virulence factors produced by T vagina/is. This study explores the expression of one particular legumain-like cysteine protease known as Tv AE 1. Furthermore, it highlights the relationship between inhibitory effects of trichomonal cells caused by sanguinarine and chelerythrine. A system for obtaining legumains by expressing it in methylotrophic yeast, Pichia pastor is, has been described. The recombinant legumains were produced and processed by the yeast to their inactive and mature forms. Secondly, T foetus cells were transfected with TvAEl construct. Localization and enzymatic studies on legumains will provide evidence into the pathogenicity ofT vagina/is. This study revealed the vesicularization of recombinantly unprocessed TvAEl proteins. Thirdly, plant derived compounds, sanguinarine (SA) and chelerythrine (CHE) were assessed in vitro for their inhibitory effects against T vagina/is and T. foetus. Treatment of SA and CHE for 24 h led to a significant inhibitory growth of in vitro cultures for all three trichomonal strains, G3, Tl and Dl, compared to untreated cells. For these bovine and human trichomonal strains, SA was slightly more effective inhibitor than CHE. With IC5o values between 3 - 8 micromolar for the alkaloids, CHE had less inhibitory effect compared to SA. These findings are significant considering the association between cysteine pro teases and trichomoniasis. Further elucidation of the exact anti protozoal mechanism of both compounds toward legumains may lead to the development of these potent agents against trichomonads.

Trichomonas vagina/is is a common sexually transmitted disease, affecting women more often than men. It has only been seen to undergo mitosis, even though published studies have confinned the organism has meiotic proteins. These meiotic proteins are known to function in other organisms with a key protein in homologous recombination, DMCl. RT-PCR analysis shows low expression ofDMCl in mitotically-growing cultures, and we found that some stresses on the organism increase DMCl expression. Polyclonal antibodies raised against DMCl protein have been used to test whole celllysates of the Tl and G3 strains of Trichomonas vagina/is but no obvious expression has been detected. We also used western blot analysis to show that superoxide dismutase is expressed in the standard lab strains Tl and G3 and immunocytochemistry studies showed that HA-tagged SOD6 protein localizes in the cytoplasm. Lastly, we found that SOD protein abundance increased in the CDC085 strain compared to Tl and G3, especially under aerobic conditions.

Trichomonas vaginalis is a protozoan parasite responsible for causing nearly eight million cases of Trichomoniasis every year in the United States. Trichomoniasis is often an asymptomatic infection, but in some cases it does lead to mild clinical manifestions. Trichomoniasis is easily treated with a single dose of Metronidazole. Drug resistance is not common, but it is on the rise. In addition to increasing rates of drug resistance, Trichomoniasis also poses a public health threat as it has been shown to increase the risk of HIV transmission. In order to combat this emerging public health threat, we must better understand the mechanism by which metronidazole exerts its action on T. vaginalis , as well as how the parasite has responded by evolving mechanisms of drug resistance on a molecular level. In order to investigate these questions, a microarray analysis of two distinct strains of T. vaginalis , one being more virulent and slightly less metronidazole sensitive, was performed. This allowed the identification of several genes that may play a role in virulence and drug susceptibility. Once these genes were identified, their differential regulation was further confirmed by Northern Blot analysis. One of these genes, Thioredoxin Reductase (TrxR) was then cloned and transfected into T. vaginalis . After confirming expression of the HA-tagged TrxR, the cell line was then used to determine the effect of over-expression of the gene on drug sensitivity. The metronidazole IC 50 for this cell line was compared to wild type cells. Additionally, immunostaining of the transfected cells was performed to determine the localization of the HA-tagged thioredoxin reductase. The results of this investigation provide further support for the role of TrxR in metronidazole activation as well as metronidazole sensitivity. Additionally, several other genes identified as differentially regulated may play a role in virulence, and should be targeted for further investigation.

Trichomonas vaginal is is the sexually transmitted agent of trichomoniasis. Although the organism is believed to only reproduce via binary fission, genes specific to 5 Meiosis and Homologous Recombination have been identified in its genome. It is unclear whether the organism has the ability to undergo sexual reproduction or if it has lost that ability over time. Aside from meiosis, these genes could be expressed for use in antigenic variation and in the creation or transfer of resistance genes to other cells. In this study, we induced the expression ofDMCl and Rad51 homologues-key players in Homologous Recombination-using a system of tetracycline induction. We localized DMCl to both the cytoplasm and the nucleus, while Rad51 is localized to the nucleus. We performed a DNA strand exchange that suggests DMCl may be capable of DNA strand exchange. We also developed a system to determine whether haploid cells of Trichomonas vaginal is are capable of cytoplasmic fusion through the use of fluorescent proteins. Specifically, this study focuses on a line of Green Fluorescent Protein-expressing cells.

Trichomonas vaginalis is an anaerobic, parasitic protozoan, responsible for trichomoniasis, the world’s most common, non-viral sexually transmitted infection. Lacking many of the defenses present in other organisms to combat oxidative stress, Trichomonas vaginalis relies extensively on the thioredoxin system—NADPH, thioredoxin reductase, and thioredoxin—as a means to protect against exposure to excess oxygen. Current trichomoniasis treatment relies exclusively on the 5-nitroimidazole drugs, but fear of drug-resistant strains and allergic reactions to 5-nitroimidazole treatment necessitate the discovery of a new treatment method for trichomoniasis. Previous research has shown that auranofin, an FDA-approved drug, was effective at inhibiting activity of one of Trichomonas vaginalis’ isoforms of thioredoxin reductase (of which the organism has five total). Our research showed that only two of the isoforms were transcribed and expressed at high levels, and that both of these isoforms were susceptible to auranofin treatment. Not only that, these two isoforms were also shown to be susceptible to various auranofin analogs, having comparable or lower IC50 values. Further tests on these analogs might show that they are actually better treatment candidates if they exhibit less symptoms than auranofin. Experiments examining how mRNA and protein levels were modulated in response to two different concentrations of auranofin treatment showed that while some isoforms show increased levels, no one isoform experienced any drastic changes. Together, this data suggests that further studies should focus on these two most highly expressed isoforms of thioredoxin reductase.